To retrospectively explore the survival predictors and treatment efficacy of advanced pneumonic-type lung adenocarcinoma (P-ADC).
Methods:
Retrospective analysis of clinical data and survival follow-up was undertaken on 41 patients with advanced P-ADC from January 1, 2009, to April 30, 2019. Analysis on tumor biomarkers such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and the cytokeratin-19-fragment (Cyfra21-1) were undertaken. The patients in this study were divided into three groups based on usage of tyrosine kinase inhibitor (TKI): TKI therapy group (including combination with chemotherapy), non-TKI therapy group (chemotherapy alone), and palliative care group.
Results:
More than half of the patients had higher levels of tumor biomarkers and the incidence of NSE was highest (81.8%), followed by CEA (74.4%) and Cyfra21-1 (74.1%). All patients had abnormal findings on chest computed tomography and with adenocarcinoma pathology. The overall survival (OS) time was 10.4 months in TKI group, 8.8 months in the non-TKI group, and 2.1 months in the palliative care group. Patients with higher level of serum Cyfra21-1 had insignificantly shorter survival time compared to those with normal Cyfra21-1 (p = 0.067). TKI therapy and non-TKI therapy provided a better prognosis prediction compared to palliative care. TKI therapy improved prognosis compared to non-TKI therapy. The comprehensive based TKI therapy provided improved OS vs the non-TKI therapy.
Conclusion:
TKI-based therapy could improve the prognosis and OS for advanced P-ADC. This study recommends the analysis of EGFR mutations for all patients with advanced P-ADC.
WeirHKAndersonRNColeman KingSM, et al. Heart disease and cancer deaths: trends and projections in the United States, 1969–2020. Prev Chron Dis2016; 13: E157.
2.
PathakVZhouC.Transbronchial lung cryobiopsy for the diagnosis of lepidic-predominant lung adenocarcinoma. Lung India2019; 36: 434–437.
3.
SmithRAAndrewsKSBrooksD, et al. Cancer screening in the United States: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin2017; 67: 100–121.
4.
LinLYanLLiuY, et al. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol2019; 12: 96.
5.
McGuireS.World Cancer Report 2014: Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr2014; 7: 418–419.
6.
LiuSChengHYaoS, et al. The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features. Ann Nucl Med2010; 24: 541–547.
7.
BrayFFerlayJSoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018; 68: 394–424.
8.
WeiJTangDNieY, et al. Clinical characteristics and prognosis of nonsurgically treated patients with pneumonic-type adenocarcinoma. Medicine2019; 98: e15420.
9.
VolpinoPD’AndreaNCangemiR, et al. Bronchioloalveolar carcinoma: clinical, radiographic, and pathological findings: surgical results. Cardiovasc Surg2001; 42: 261–267.
10.
WislezMMassianiMAMilleronB, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest2003; 123: 1868–1877.
11.
YuanDMYaoYWLiQ, et al. Recurrent “pneumonia” in left lower lobe lasting for 8 years: a case report. Transl Lung Cancer Res2016; 5: 356–362.
McAleeseJTaylorAWallsGM, et al. Differential relapse patterns for non-small cell lung cancer subtypes adenocarcinoma and squamous cell carcinoma: implications for radiation oncology. Clin Oncol2019; 31: 711–719.
14.
GarfieldDHCadranelJLWislezM, et al. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol2006; 1: 344–359.
15.
AustinJHGargKAberleD, et al. Radiologic implications of the 2011 classification of adenocarcinoma of the lung. Radiology2013; 266: 62–71.
16.
KrisMGGiacconeGDaviesA, et al. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol2006; 1 (9 suppl): S32–S36.
17.
BalestraRSelvarajuABenzaquenS, et al. Pneumonic-type mucinous lung adenocarcinoma diagnosed by transbronchial cryobiopsy. Respirol Case Rep2017; 5: e00222.
18.
YamakawaHTakayanagiNIshiguroT, et al. Favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma. Intern Med2013; 52: 2781–2784.
19.
WestHJ.Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. Clin Adv Hematol Oncol2014; 12: 593–600.
20.
LiuJShenJYangC, et al. High incidence of EGFR mutations in pneumonic-type non-small cell lung cancer. Medicine2015; 94: e540.
21.
NandaSDasRCoxDN, et al. Structural plasticity in dendrites: developmental neurogenetics, morphological reconstructions, and computational modeling. In: PetrosiniL, ed. Neurobiological and Psychological Aspects of Brain Recovery. Contemporary Clinical Neuroscience, Springer; 2017.
22.
DetterbeckFCMaromEMArenbergDA, et al; IASLC Staging and Prognostic Factors Committee; Advisory Boards; Multiple Pulmonary Sites Workgroup. The IASLC Lung Cancer Staging Project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol2016; 11: 666–680.
23.
DuruisseauxMAntoineMRabbeN, et al. The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation. Lung Cancer2014; 83: 334–340.
24.
IchiroYDaigoKTaroO, et al. Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg2006; 81: 1189–1193.
25.
SantoroILRamosRPFranceschiniJ, et al. Non-small cell lung cancer in never smokers: a clinical entity to be identified. Clinics2011; 66: 1873–1877.
26.
YanoTHaroAShikadaY, et al. Non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features. Int J Clin Oncol2011; 16: 287–293.
27.
PujolJBoherJGrenierJ, et al. Cyfra21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer2001; 31: 221–231.
28.
AkiraMAtagiMKawaharaM, et al. High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. Am J Roentgenol1999; 173: 1623–1629.
29.
WalkerCMAbbottGFGreeneRE, et al. Imaging pulmonary infection: classic signs and patterns. Am J Roentgenol2014; 2: 479–492.
30.
GriffithsDJMartineauHMCousensC.Pathology and pathogenesis of ovine pulmonary adenocarcinoma. J Comp Pathol2010; 142: 260–283.
31.
SatoruN.CT findings of pneumonic adenocarcinoma: comparison between invasive mucinous adenocarcinoma and nonmucinous adenocarcinoma. Global J2014; 14: version 1.0.
32.
The structural and physiologic basis of respiratory disease. In: WilmottRBushADeterdingR, et al, eds. Kendig’s Disorders of the Respiratory Tract in Children, 9th ed.Amsterdam: Elsevier; 2019: 63–100.
33.
TravisWDBrambillaENoguchiM, et al. American Thoracic Society: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc2011; 8: 381–385.
34.
TorneselloMLLositoSBenincasaG, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol2011; 121: 32–42.
35.
WatanabeHSaitoHYokoseT, et al. Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma. Ann Thorac Surg2015; 99: 975–981.
36.
IrinaV.Radionuclides for imaging and therapy in oncology. In: ChenXWongS eds. Cancer Theranostics2014; 285–325.
37.
KongkuoLTianchengHShengX, et al. Multimodality image-guided lung intervention systems. In: ChenXWongS, eds. Cancer Theranostics2014; 161–186.
HeymannJJBulmanWASwinarskiD, et al. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol2017; 125: 896–907.
40.
HolstSWuhrerMRomboutsY.Glycosylation characteristics of colorectal cancer. Adv Cancer Res2015; 126: 203–256.
41.
XipingZHongjianYRuipingZ.Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions. Biosci Rep2019; 39: BSR20190230.
42.
HaberDAVelculescuVE.Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov2014; 4: 650–661.
43.
JoosseSAGorgesTMPantelK.Biology, detection, and clinical implications of circulating tumor cells. EMBO Molec Med2015; 7: 1–11.
44.
CabelLProudhonCMarianiP, et al. Circulating tumor cells and circulating tumor DNA: what surgical oncologists need to know. Eur J Surg Oncol2017; 43: 949–962.
45.
JiHKBoasNYunJC, et al. Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation. Metab Chem Biol2018; 78: 4482–4496.
46.
RangachariDVander LaanPASheaM, et al. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 (>50% expression in lung adenocarcinoma). J Thorac Oncol2017; 12: 878–883.
47.
MidhaADeardenSMcCormackR.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res2015; 5: 2892–2911.
48.
WestHLFranklinWAMcCoyJ, et al. Gefitinib therapy in advanced bronchioloalveolar cancer: Southwest Oncology Group Study S0126. J Clin Oncol2006; 24: 1807–1813.
49.
NakatomiKNakamuraYTetsuyaI, et al. Treatment with gefitinib after erlotinib-induced liver injury: a case report. J Med Case Rep2011; 5: 593.
50.
DaoudALaktinehAEl ZeinS, et al. Unusual presentation of primary lung adenocarcinoma mimicking pneumonia: case report and literature review. Respir Med Case Rep2019; 28: 100881.
51.
OxnardGRMillerVA.Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology2010; 24: 392–399.
52.
WuHBWangLWangQ, et al. Adenocarcinoma with BAC features presented as the nonsolid nodule is prone to be false-negative on 18F-FDG PET/CT. BioMed Res Int2015; 243681.
